期刊文献+

RNA干扰下调HE4基因表达对人卵巢癌SK-OV-3细胞增殖和侵袭的影响 被引量:3

Effect of HE4 gene silenced by siRNA on the proliferation and invasiveness of ovarian cancer cell SK-OV-3
暂未订购
导出
摘要 目的应用RNA干扰技术下调人附睾蛋白HE4基因表达水平,观察HE4对人卵巢癌SK-OV-3细胞增殖和侵袭能力的影响。方法化学合成3对HE4特异性小分子干扰RNA(siRNA),脂质体法转染人卵巢癌细胞系SK-OV-3(HE4-siRNA组),同时以非特异序列siRNA转染的SK-OV-3细胞(阴性对照组)和正常培养的SK-OV-3细胞(正常对照组)为对照,于转染后48 h,采用实时荧光定量PCR技术(RT-qPCR)和Western blot方法分别检测HE4 mRNA及蛋白表达水平。采用CCK8试剂盒检测卵巢癌细胞增殖活性的变化,穿膜小室模型测定HE4对细胞侵袭能力的影响。结果与正常对照组相比,HE4-siRNA转染卵巢癌SK-OV-3细胞48 h后,HE4 mRNA的表达水平显著下降,仅为正常对照组的12.7%(P<0.01),与之相应HE4蛋白表达也显著下降,而转染非特异序列的阴性对照组与正常对照组之间的差异无统计学意义(P>0.05)。HE4-siRNA下调卵巢癌SK-OV-3细胞HE4表达后,细胞增殖受到明显抑制,细胞增殖活性仅为正常对照组的60%,阴性对照组细胞增殖未见明显变化。体外侵袭实验显示,HE4-siRNA组穿膜细胞数为每视野(21.8±2.86)个,显著低于正常对照组(187.4±11.17)个(P<0.01)和阴性对照组(177.8±9.76)个(P<0.01),而阴性对照组和正常对照组两组之间差异无统计学意义(P>0.05)。结论 HE4特异性siRNA能成功下调SK-OV-3细胞中HE4基因的表达,显著降低卵巢癌细胞增殖和侵袭能力,HE4有可能成为人卵巢癌侵袭转移防治的重要靶点。 Objective To investigate the effect of HE4 gene knocked down by small interfering RNA (siRNA) on proliferation and invasiveness of ovarian cancer cell SK-OV-3. Methods 3 pairs of synthetic siRNAs targeted HE4 gene were transiently transfected into SK-OV-3 cells by liposomal method (HE4-siRNA group), siRNA of scrambled sequence were transfected at the same time as a negative control, and normal cultured SK-OV-3 without any transfection were used as normal control. HE4 expression level in SK-OV-3 cells was determined using real-time quantitative PCR method and Western blot. CCK8 assay was used to identify proliferation of SK-OV-3 cells. The invasive ability of SK-OV-3 cells was measured by transmembrane (Transwell) small chamber method. Results The HE4 mRNA level in HE4-siRNA group cells was significantly decreased to about 12.7% of that in the normal control group. Western blot results showed that the HE4 protein level was the same trend with the mRNA one. However, there existed no statistically significant differences in HE4 expression levels between negative control group and normal control group (P 〉 0.05). The inhibitory percentage of cell proliferation was about 60% of that in normal control group since HE4 expression was knocked down using HE4-siRNA. There was no significant difference in cell proliferation between negative control group and normal control group. In the invasion assay, the number of cells that invaded through the artificial basement membrane in HE4-siRNA group was (21.8 ± 2.86), which was significantly lower than those in normal group and negative control group (187.4 ±11.17) (P 〈 0.01) and (177.8 ± 9.76) (P 〈 0.01) respectively, while difference between the 2 control groups were not statistically significant (P 〉 0.05). Conclusion Downregulation of HE4 expression by siRNA inhibits invasion and proliferation of ovarian cancer cell.
出处 《中国医药生物技术》 2014年第1期20-25,共6页 Chinese Medicinal Biotechnology
基金 广东省医学科研基金(A2010660)
关键词 卵巢肿瘤 RNA干扰 细胞增殖 瘤侵润 HE4 Ovarian neoplasms RNA interference Cell proliferation Neoplasm invasiveness HE4
  • 相关文献

参考文献14

  • 1Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med, 2008, 2(3):291-303.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1):11-30.
  • 3Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 1991, 45(2):350- 357.
  • 4Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 1999, 238(2): 375-385.
  • 5Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 2000, 60(22):6281-6287.
  • 6Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003, 63(13):3695-3700.
  • 7Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, et al. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA 125, and CEA and patient's age. Gynecol Oncol, 2013, 129(3):467-471.
  • 8Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2013, 167(1):81-85.
  • 9Moore RG, MeMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 2009, 112(1):40-46.
  • 10Trudet D, Tetu B, Gregoire J, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol, 2012, 127(3):511-515.

同被引文献38

  • 1Angioli R,Miranda A,Aloisi A,et al.A critical review on HE4 performance in endometrial cancer: where are we now?[J].Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine,2013,35(2):881-887.
  • 2Moore R G,Brown A K,Miller M C,et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J].Gynecologic Oncology,2008,10(2):196-201.
  • 3Li J,Dowdy S,Tipton T,et al.HE4 as a biomarker for ovarian and endometrial cancer management[J].Expert Review of Molecular Diagnostics,2009,9(6):555-566.
  • 4Kirchhoff C,Habben I,Ivell R,et al.A major human epididymis-specific c DNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J].Biology of Reproduction,1991,45(2):350-357.
  • 5Desouza L V,Grigull J,Ghanny S,et al.Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry[J].Molecular & Cellular Proteomics Mcp,2007,6(7):1170-1182.
  • 6Li H,Desouza L V,Ghanny S,et al.Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry[J].Journal of Proteome Research,2007,6(6):2615-2622.
  • 7Chhikara N,Saraswat M,Tomar A K,et al.Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor[J].Plos One,2012,7(11):e47 672.
  • 8Morisset D,Bourbonnais Y,Tremblay G M.Proteins with whey-acid-protein motifs and cancer[J].Lancet Oncology,2006,7(2):167-174.
  • 9Micci F,Teixeira M R,Haugom L,et al.Genomic aberrations in carcinomas of the uterine corpus[J].Genes Chromosomes & Cancer,2004,40(3):229-246.
  • 10Dekken H V,Alers J C,Riegman P H J,et al.Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions[J].American Journal of Pathology,2001,158(6):1961-1967.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部